I-Mab (IMAB) to Release Quarterly Earnings on Thursday

I-Mab (NASDAQ:IMAB) is anticipated to announce its earnings results before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.

I-Mab Stock Down 1.1 %

IMAB stock opened at $0.80 on Wednesday. I-Mab has a twelve month low of $0.76 and a twelve month high of $2.00. The business’s 50-day moving average price is $0.98 and its 200-day moving average price is $1.06.

Wall Street Analyst Weigh In

A number of research analysts recently commented on IMAB shares. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of I-Mab in a report on Friday, November 15th. Brookline Capital Management raised I-Mab to a “strong-buy” rating in a research note on Thursday, February 27th.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.